Treatment of Urinary Tract Infections in Hospitalized Adults
Abstract
Background The purpose of the study was to evaluate whether ceftriaxone therapy would result in less clinical failure than levofloxacin therapy in hospitalized adults treated for urinary tract infections (UTIs). Methods This was a single-center, retrospective cohort study of hospitalized adult patients with UTI as admitting diagnosis from 2012 to 2017. Patients were included in the study if they received ≥48 continuous hours of levofloxacin or ceftriaxone. The primary end point was clinical failure, defined as a composite of attributable mortality, in vitro resistance, or change of antimicrobial class. All variables from bivariate analysis with significance P < 0.20 were included in a multivariate regression model completed in the backward stepwise method to determine predictors of clinical failure. Results Of the 325 patients who met study inclusion criteria, 187 (57%) received ceftriaxone and 138 (43%) received levofloxacin. Clinical failure occurred in 11% of patients treated with ceftriaxone and 22% of patients treated with levofloxacin (P < 0.01). Ceftriaxone therapy was associated with reduced odds of clinical failure when controlling for chronic kidney disease, history of UTIs, cirrhosis, and fever at therapy initiation. Conclusions Patients treated with ceftriaxone experienced significantly less clinical failure than patients treated with levofloxacin despite low baseline resistance rates.
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 325 participants or records.
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.